OR WAIT null SECS
In the present investigation, the fixed-dose combination (FDC) tablet of Atorvastatin calcium and Ezetimibe was prepared by a quality-by-design approach using two-level factorial design.
In the present investigation, the fixed-dose combination (FDC) tablet of Atorvastatin calcium and Ezetimibe was prepared by a quality-by-design approach using 23 factorial design. Precompression and post-compression parameters were determined indicating excellent flow properties of granules as well as good tableting characteristics of the final tablets. Dissolution study showed higher drug release nearly 80% within 30 min for all prepared batches attributed to conversion from crystalline to amorphous form of the drug. ANOVA studies revealed that there was a linear correlation between the predicted, and the observed responses gave higher values of r2, indicating excellent fitting of the model (P < 0.001). Thus, the prepared FDC tablet executed a good relationship between selected critical formulation parameters and critical quality attributes. The drug release rate obtained met the selected dissolution criteria.
Submitted: August 5, 2020.
Accepted: October 12, 2020.
Rajendra Kotadiya,* firstname.lastname@example.org; +91 8160701232, is assistant professor, Krunal Jasani is PG student, and Gayatri Patel is professor, all at Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology (CHARUSAT), Changa, Gujarat, India.
*To whom all correspondence should be addressed.
Vol. 45, No. 6
When referring to this article, please cite it as Rajendra Kotadiya, Krunal Jasani, and Gayatri Patel, “Using Quality by Design to Develop Fixed-Dose Combination Tablets,” Pharmaceutical Technology 45 (6) 2021.